Ozempic and Vascular Health: What the Science Really Says

Citable definition: Ozempic is the brand name for semaglutide, a medication in the GLP-1 receptor agonist class (glucagon-like peptide-1, a gut hormone that regulates blood sugar and appetite), originally developed for type 2 diabetes and whose cardiovascular and metabolic effects have been the subject of intensive research since 2018.

You have heard about it on television, on social media, perhaps even in your doctor’s waiting room. In just a few years, Ozempic has become one of the most talked-about medications on the planet. But beyond the media hype, what does the science actually say about its effects on your blood vessels, your veins, and your cardiovascular health? That is what we will explore here, with solid sources and a vascular specialist’s perspective.

What Is Ozempic, Exactly?

Ozempic (injectable semaglutide) belongs to a family of medications called GLP-1 receptor agonists — molecules that mimic a natural gut hormone. By stimulating these receptors, semaglutide acts on several fronts simultaneously:

• It lowers blood glucose by stimulating insulin secretion
• It reduces appetite, often leading to significant weight loss
• It slows gastric emptying (the passage of food from the stomach to the intestines)

Approved internationally for type 2 diabetes, it is administered as a weekly subcutaneous injection (under the skin). Its cousin, Wegovy (semaglutide at a higher dose), is specifically indicated for obesity.

An analysis of prescribing trends in Denmark between 2018 and 2023 (Mailhac et al., 2024) documented an explosion in semaglutide use, including outside its approved indications — particularly for weight loss in people without diabetes. This phenomenon, known as off-label use, is accompanied by massive public interest confirmed by a Google Trends analysis (Han et al., 2024) revealing a dramatic surge in global searches for “Ozempic weight loss.”

Ozempic and Blood Vessels: What Are the Concrete Effects?

This is where the vascular interest of Ozempic becomes particularly relevant for our readers at Petit Veinard.

A Protective Effect on the Heart and Arteries

The most recent studies are encouraging. The SOUL randomized clinical trial, whose results were published in Circulation in 2025, evaluated oral semaglutide in type 2 diabetes patients at high cardiovascular risk. Prespecified analyses showed a reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death), independent of other protective treatments such as SGLT-2 inhibitors (another class of antidiabetic medications).

In parallel, a study published in Circulation in February 2026 (target trial emulation) compared GLP-1 agonists with DPP-4 inhibitors and SGLT-2 inhibitors: patients on GLP-1 agonists had a reduced risk of hospitalization for heart failure (a condition where the heart no longer pumps blood effectively enough).

To learn more about the links between cardiovascular disease and vascular health, see our section on arteries.

A Protective Effect on the Kidneys

The kidneys and blood vessels are intimately connected: chronic kidney disease (CKD) accelerates arterial aging. A systematic meta-analysis published in 2026 in Renal Failure (Wang Y et al.) involving GLP-1 agonists in CKD patients concluded there are significant cardioprotective and renal effects: reduced proteinuria (abnormal protein in the urine, a sign of kidney damage), improved glomerular filtration rate (the kidneys’ ability to filter blood), and fewer cardiovascular events.

The Connection to Diabetic Foot and Peripheral Artery Disease

Online search data show strong public concern about diabetic foot (+400% in trending searches) and peripheral artery disease (PAD — narrowing of the leg arteries by fatty plaques, +540%). Both conditions are directly linked to poorly controlled diabetes.

By improving blood sugar control and reducing weight, Ozempic could indirectly protect the leg arteries. But caution is warranted: Ozempic is not a treatment for PAD, and any suspicion of peripheral artery disease requires a specialized vascular surgery consultation.

Discover our complete guide on peripheral artery disease and arterial health.

Ozempic and Heavy Legs: The Venous Connection

Heavy legs (+86% in trending searches) are one of the most common symptoms of chronic venous insufficiency (CVI — poor blood circulation in the leg veins, from bottom to top). Excess weight is one of the main aggravating factors for CVI: it increases venous pressure and slows venous return.

By enabling significant weight loss (up to 10 to 15% of body weight according to clinical trials), Ozempic can indirectly relieve venous symptoms. Less weight on the legs means less pressure in the veins and less sensation of heaviness.

However, Ozempic does not treat varicose veins, does not repair failing venous valves, and does not replace specific venous treatments (compression therapy, sclerotherapy, surgery). For appropriate management, see our section on veins.

What Are the Side Effects to Know About?

Like any medication, Ozempic is not without risks. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation — especially at the start of treatment.

From a vascular and metabolic standpoint, the safety profile is generally reassuring based on current data. The question of thyroid risk was raised after animal studies. A 2024 systematic review (Feier CV et al.) concluded that the risk of thyroid carcinoma in humans remains theoretical and unconfirmed at this stage, but warrants regular medical monitoring.

Ozempic Versus Other Treatments: An Economic Comparison

An analysis published in 2026 in the Journal of Medical Economics (Kanumilli et al.) compared the annual cost per patient achieving therapeutic goals between tirzepatide (a competing medication in the same class) and subcutaneous semaglutide in the United Kingdom. These cost-effectiveness analyses are important for understanding coverage and access-to-care challenges — an active debate in many healthcare systems worldwide.

Prevention: What You Can Do Every Day

Whether you are taking Ozempic or not, here are concrete steps to protect your blood vessels:

• Walk 30 minutes a day: walking activates the calf muscle pump and improves venous return
• Adopt a Mediterranean diet: rich in vegetables, oily fish, and olive oil, it protects the arteries
• Wear compression stockings if you have heavy legs, especially during prolonged standing
• Quit smoking: tobacco is the leading risk factor for peripheral artery disease
• Maintain a healthy weight: every kilogram lost reduces venous pressure by approximately 2 mmHg
• Monitor your blood sugar regularly if you have diabetes

Find our detailed advice on vascular prevention.

When Should You See Your Doctor?

See a doctor promptly if you experience:

• Calf pain that appears during walking and disappears at rest (intermittent claudication — a possible sign of peripheral artery disease)
• A cold, bluish foot or a wound that does not heal (possible vascular emergency)
• Large or painful varicose veins
• Heavy legs worsening despite lifestyle measures
• Any unusual side effects while taking Ozempic

And if you are considering taking Ozempic for weight loss without having diabetes, talk to your doctor first. Off-label use is not without consequences: a qualitative study conducted in Denmark in 2026 (Guldhammer et al., Scandinavian Journal of Primary Health Care) highlights the complex social and medical issues surrounding semaglutide use outside the diabetic context, including stigmatization and lack of proper support.

When in doubt, consult your primary care physician or a vascular specialist.

Read also:

• Diet and Vascular Health: Protecting Your Veins and Arteries
• Varicose Veins: Causes, Symptoms, and Complete Treatment Guide
• Exercise and Blood Circulation: Best Activities for You

Sources

1. Guldhammer A, Drivsholm T, Tomova-Olsen SA, Tranberg Jensen K. A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark. Scandinavian Journal of Primary Health Care. 2026. DOI: 10.1080/02813432.2026.2636584

2. Kanumilli N et al. Annual pharmacy cost per patient achieving composite treatment endpoints: tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK. Journal of Medical Economics. 2026. DOI: 10.1080/13696998.2026.2631920

3. Wang Y, Feng L, Wang Y et al. Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis. Renal Failure. 2026. DOI: 10.1080/0886022X.2026.2620155

4. Risk of Heart Failure Hospitalization for GLP-1 Receptor Agonists Versus DPP-4 Inhibitors or SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Target Trial Emulation. Circulation. 2026 Feb 24. DOI: 10.1161/CIRCULATIONAHA.125.075157

5. Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial. Circulation. 2025 Jun 10. DOI: 10.1161/CIRCULATIONAHA.125.074545

6. Han SH, Safeek R, Ockerman K, Trieu N et al. Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google Trends analysis. 2024.

7. Feier CVI, Vonica RC, Faur AM, Streinu DR et al. Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (Ozempic) therapy for diabetes mellitus and obesity: A systematic literature review. 2024.

8. Mailhac A, Pedersen L, Pottegard A et al. Semaglutide (Ozempic) Use in Denmark 2018 Through 2023 — User Trends and off-Label Prescribing for Weight Loss. 2024.

Medical disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, a diagnosis, or a prescription. Ozempic (semaglutide) is a prescription medication whose indication and dosage must be evaluated by a qualified physician based on your individual situation. Never modify your treatment without your doctor’s advice. In case of a vascular emergency (chest pain, sudden leg pain, a wound that does not heal), call emergency services (911 in the US, 999 in the UK, 112 in the EU) or go to your nearest emergency department. Petit Veinard assumes no liability for the use of this information for self-diagnosis or self-medication.